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Abstract
Background: CD4 testing is the recognized gold standard used to stage HIV/AIDS, guide treatment decisions for
HIV-infected persons and evaluate effectiveness of therapy. The need for a less expensive surrogate marker that can
be used in resource-limited setting is however necessary. The study sought to assess the suitability of Total
lymphocyte count (TLC) as a surrogate marker for CD4 count in resource-limited localities in Ghana.
Methods: This observational study was conducted at the Central Regional Hospital, which has one of the
established antiretroviral therapy centres in Ghana. A total of one hundred and eighty-four (184) confirmed HIV I
seropositive subjects were included in the study. Blood samples were taken from all the subjects for estimation of
CD4 and total lymphocyte counts. The study subjects were further categorised into three (3) groups according to
the Centers for Disease Control and Prevention (CDC) classification criteria as follows: CD4 counts (1)≥ 500 cells/
mm3 (2) 200–499 cells/mm3 and (3) <200 cells/mm3. Positive predictive value (PPV), negative predictive value (NPV),
sensitivity and specificity of various TLC cut-offs were computed for three groups. Correlation and Receiver Operator
Characteristic analysis was performed for the various CD4 counts and their corresponding Total Lymphocyte count
obtained.
Results: The sensitivity, specificity, positive and negative predictive values of TLC 1200 cells/ mm3 to predict CD4
count were <200 cells/mm3 72.2%, 100%, 100% and 95.7% respectively. A TLC of 1500 cells/ mm3 was found to
have maximal sensitivity (96.67%), specificity (100%), PPV (100%) and NPV (75.0%) for predicting a CD4 cell count of
200–499 cell/mm3. A TLC of 1900 cells/mm3 was also found to have a maximal sensitivity (98.45%), specificity
(100%), PPV (100%) and NPV (100%) for predicting CD4 count ≥500 cells/mm3. A positive correlation was noted
between 184 paired CD4 and TLC counts (r = 0.5728).
Conclusion: Total Lymphocyte count can therefore adequately serve as a surrogate marker for CD4 count in HIV
patients who are naïve for antiretroviral therapy in resource-limited areas.
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Background
Worldwide estimates of people living with Human Immu-
nodeficiency Virus was approximately 32 million in 2007
with thousands of people getting infected every day [1].
Most people living with HIV are from developing countries
with less than 5% receiving antiretroviral therapy [2]. In
2009, an estimated 2.6 million people became infected out
of which approximately 1.8 million were from sub-Saharan
Africa [2]. The initiation of antiretroviral therapy is based
on CD4 counts of less than 350 cells/mm3 according to
the World Health Organization (WHO) and Centre for
Disease Control (CDC). The determination of CD4 count
however in resource-limited localities is difficult. A total
lymphocyte count (TLC) of <1200 cells/mm3 has been
recommended in addition to WHO staging (stage II) of
the disease, for the initiation of antiretroviral therapy in
such localities [3]. The use of absolute lymphocyte count
as a marker for HIV progression has been argued in many
quarters over the years [4-7]. Studies have suggested that
when the absolute lymphocyte count is used in conjunc-
tion with blood hemoglobin, it gives a more sensitive
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marker for HIV progression [6,8] with other studies discre-
diting the use of TLC in such settings [9,10].
The above disagreements in various study settings
necessitated the need for this study to be carried out.
The aim of this study was therefore to ascertain existing
relationships between CD4 count and TLC and to fur-
ther ascertain if TLC could be used as a surrogate mar-
ker for CD4 counts in the initiation of antiretroviral
therapy in resource-limited localities in Ghana.
Methods
This observational study was conducted at the Central
Regional Hospital which is one of the established centres
providing anti-retroviral therapy (ART) and located at
Cape Coast, the capital of the Central region of Ghana.
The study was conducted between August 2007 and May
2008. Blood samples were taken from the subjects before
the initiation of ART. This study was approved by the
Committee on Human Research, Publications and Ethics
(CHRPE), School of Medical Sciences, Kwame Nkrumah
University of Science & Technology (KNUST), Kumasi.
All patients enrolling in the study completed a written
informed consent form in accordance with the Helsinki
Declaration. After obtaining consent, demographic ques-
tionnaires were completed.
Total lymphocyte count and CD4 cell count
Blood (5 ml) was drawn into Vacutainer tubes with Ethy-
lenediaminetetraacetic acid (EDTA) and used to deter-
mine CD4 cell count and TLC. Samples from the
patients were analysed within 2 to 4 hours of collection.
TLC was determined by using an automated blood
analyzer (CELL-DYN 1800, Abbott Laboratories Diag-
nostics Division, USA) and CD4 T lymphocytes count
was determined using the Becton Dickinson (BD) FAS-
Count system (Becton, Dickinson and Company, Califonia,
USA). The BD FASCount system used flow cytometry for
the quantification of the CD4 T Lymphocytes.
Subjects
A total of one hundred and eighty-four (184) HIV I sero-
positive subjects who were determined by rapid immuno-
chromatographic HIV test kit First Response HIV 1–2 and
confirmed with an enzyme-linked immunosorbent assay
were included in the study after giving informed consent.
The study subjects were categorised into three (3) groups
according to the Centers for Disease Control and Preven-
tion Criteria (CDC) classification system that emphasizes
the importance of CD4+ T lymphocyte testing in clinical
management of HIV-infected persons. The groups are: CD4
counts (1) ≥500 cells/mm3; (2) 200–499 cells/mm3; and
(3) <200 cells/mm3. Inclusion criteria were at least
18 years of age and HIV-1 seropositivity. Exclusion criteria
were antiretroviral therapy and co-morbidity with other
medical conditions (e.g. tuberculosis, endocarditis and
acute viral infections) which could greatly modify haem-
atologic parameters.
Statistical analysis
The results were given as mean± Standard error of mean
(SEM). Correlations were evaluated using the Pearson’s
correlation test. Sensitivity, specificity, positive and nega-
tive predictive values with 95% confidence intervals (CIs)
of various cut-off points of the TLC to predict CD4+ T-
cell count ≥500 cells/mm3, 200–499 cells/mm3 and
< 200 cells/mm3 were calculated. For all statistical com-
parisons, the level of significance was set at p< 0.05.
Data were analyzed using GraphPad Prism for Windows
version 4.02 (GraphPad Software, San Diego, CA, USA).
Results
The demographic characteristics of the subjects are
shown in Table 1. Table 1 shows the means of the ages,
CD4 count and TLC of the three groups and these
values as expressed as means ± Standard error of the
Mean (SEM). Various TLC cut-off, sensitivity, specifi-
city, positive and negative predictive values for the
three CD4 groups are shown in Tables 2. Considering
the best cut-off values of TLC, that are with the highest
sensitivity and specificity combinations, a TLC of
1200cells/mm3 was found to have maximal sensitivity
of 72.2% and specificity of 100% for predicting a CD4
cell count of< 200 cells/mm3. The best TLC cut-off for
predicting CD4 count between 200–499 cells/mm3 with a
maximal sensitivity of 96.67% and specificity of 100% was
1500 cells/mm3 and CD4 count ≥500 cells/mm3 with max-
imal sensitivity of 98.45% and specificity of 100% was 1900
cells/mm3 as shown in Table 2. Figure 1 shows the ROC
curve for the different groups of CD4 counts. The various
areas under the curves for the various CD4 groups
(AUC) are also shown in Figure 1. The AUC of the vari-
ous groups were high (closer to 1) making TLC a perfect
substitute for CD4 count. A positive Pearson’s correl-
ation coefficient (r) of 0.5728 (p< 0.0001) was realised
when TLC and CD4 count of the whole group was ana-
lysed as shown in Figure 2. A positive correlation
(r = 0.7220, p< 0.0001) was demonstrated between TLC
and CD4 count for the group with CD4 count
<200cells/mm3. A positive correlation of (r = 0.4106,
p = 0.056) and (r= 0.480, p = 0.006) was also demonstrated
for the groups with CD4 between 200–499 cells/mm3 and
>500 cells/mm3 respectively.
Discussion
Depletion of lymphocytes, primarily of the CD4 cell subset
subsequent to cellular CD4 immunodeficiency has been
noted as the hallmark of HIV infection [11,12] and CD4
count has been established as the gold standard for staging
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HIV/AIDS, guiding treatment decisions for HIV-infected
persons and evaluate effectiveness of therapy. Establishing a
cut-off value for TLC so as to be used as surrogate marker
for CD4 in staging, monitoring and as a guide to treatment
decisions in HIV infected persons in resource-limited set-
tings has been argued [10]. But in areas where viral loads
and CD4 counts are absent, using the current WHO guide-
lines which propose the use of TLC in conjunction with
clinical data as a criterion for the initiation of ART is the
next option [10]. Threshold analysis was done in this study
to find the ability of TLC to predict CD4 counts at three
different levels thus CD4< 200 cells/mm3, CD4 between
200–499 cells/mm3 and CD4 ≥500cells/mm3.
The study found that a TLC of 1200 cells/mm3 had
a maximal sensitivity of 72.2% and a specificity of
100% for a CD4 count <200 cells/mm3 with a PPV
of 100% and NPV of 95.7%. These maximal sensitiv-
ity, specificity, PPV and NPV obtained at this thresh-
old from this study shows a strong relationship
between CD4< 200 cells/mm3 and TLC, making the
use of TLC as a surrogate marker in remote and
deprived areas of Ghana where there is scarcity of la-
boratory technologies (i.e. CD4 equipment not avail-
able) a good choice. Total lymphocyte count at a
cut-off of 1200 cells/mm3 is a good substitute for
CD4< 200cell/mm3 in remote and deprived areas of
Ghana: thus 3 in 4 individuals would be given the
needed medication if a total lymphocyte count of
1200 cells/mm3 were used, as recommended by the
WHO. This finding is consistent with other reports
[5,6,13,14]. Spacek et al [6], found sensitivity and
specificity of 70.7% and 81.7% with Badri & Wood
[13] also finding a sensitivity of 83.4% and a specifi-
city of 87.3%. Kumarasamy et al [5] also had similar
sensitivity and specificity of 73% and 88%
respectively.
However there have been conflicting results that has
been reported [10,15,16]. These reports found low sensi-
tivity and specificity between CD4 count and TLC and
therefore suggested that TLC could not be used as a sur-
rogate marker.
Daka & Loha [10] found the sensitivity, specificity,
positive and negative predictive values of TLC< 1200
cells/mm3 to predict CD4 count< 200 cells/mm3 to be
41%, 83.5%, 87.9% and 32.5%, respectively. Findings of
such studies are obviously conflicting in different coun-
tries. These differences could be due to different ethnic,
racial, epidemiological and socioeconomic factors [17].
The study was also able to establish different cut-
off of TLC for those with CD4 between 200–499
cells/mm3 and those with CD4 count ≥500 cells/
mm3. The maximal cut-off for those with CD4 be-
tween 200–499 cells/mm3 was 1500 cells/mm3 and
that of those with CD4 count ≥500 cells/mm3 was




Age (years) 37.00 ± 1.61 34.71 ± 1.18 32.79 ± 1.10
Number of subjects 71(38.59%) 60 (32.61%) 53 (28.80%)
Sex
Male 31 (43.67%) 23 (38.33%) 19 (35.85%)
Female 40 (56.33%) 37 (61.67%) 34 (64.15%)
CD4 (cells/mm3) 95.95 ± 8.96 325.5 ± 13.26 812.5 ± 47.86
TLC (cells/mm3) 1018 ± 105.80 1896 ± 109.00 2292 ± 125.4
The values are expressed as mean± SEM.




Sensitivity (%) 95% CI Specificity (%) 95% CI PPV (%) NPV (%)
1000 72.22 46.52 to 90.31 94.44 72.71 to 99.86 100 91.7
CD4 count <200 1200 72.22 46.52 to 90.31 100 81.47 to 100.0 100 95.7
(cells/mm3) 1400 66.67 40.99 to 86.66 100 81.47 to 100.0 77.8 94.1
1600 55.56 30.76 to 78.47 100 81.47 to 100.0 65.6 91.7
1000 100 88.4 to 100 66.67 9.4 to 99.2 96.8 100
CD4 count 200–499 1200 100 88.4 to 101 67.67 9.4 to 99.3 96.7 66.7
(cells/mm3) 1500 96.67 82.8 to 99.9 100 29.2 to 100 100 75.0
1600 93.33 77.9 to 99.2 100 29.2 to 101 100 60.0
1700 95.45 77.2 to 99.9 63.64 30.8 to 89.1 84.0 87.5
CD4 count ≥500 1750 96.45 77.2 to 99.10 72.73 39.0 to 94.0 87.5 88.9
(cells/mm3) 1800 97.45 77.2 to 99.11 90.91 58.7 to 99.8 95.5 90.9
1900 98.45 77.2 to 99.12 100 71.5 to 100 100 91.7
TLC-Total lymphocyte count; PPV-Predictive positive value; NPV-Negative predictive value; 95% CI- 95% Confidence interval.
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Figure 2 Correlation between Total Lymphocyte Count and (A) the whole group (B) CD4< 200 cells/mm3 (C) CD4 200–499 cells/mm3
and (D) CD4> 500 cells/mm3.
Figure 1 ROC curve for A. CD4< 200 cells/mm3, B. CD4
200–499 cells/mm3 and C. CD4 >500 cells/mm3.
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1900 cells/mm3. This can help in taking decisions as
to when to initiate ART in resource-limited setting in
Ghana where TLC measurement can easily be done.
From the ROC analysis, the AUC were high for those
with CD4 count <200 cells/mm3, 200–499 cells/mm3
and ≥500 cells/mm3 making the use of TLC a good sub-
stitute surrogate marker for CD4 count in resource-
limited settings.
A positive correlation was established between TLC and
CD4 count (r = 0.5728, p< 0.0001) of the whole group.
There was even a stronger positive correlation in TLC
and CD4 counts of those with CD4 <200 cells/mm3
(r = 0.7220, p< 0.0001). Other authors also obtained a
stronger correlation between these parameters. These
include Jacobson et al [18], who had r= 0.68; Badri &
Wood [13], who also had r = 0.61; and Pascale et al [19],
who had r= 0.68.
Conclusion
The findings suggest that TLC, which is relatively inex-
pensive and available, is a reasonably accurate tool that
can serve as a surrogate marker in HIV patients who are
naive to antiretroviral therapy as to when to initiate anti-
retroviral therapy in resource-limited settings.
Limitations
Considering the number of subjects that were enrolled
during study period, and the fact that all the subjects
were naive for antiretroviral therapy, interpretation of
the results obtained should be done with caution.
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